N(6)-methyladenosine-mediated miR-380-3p maturation and upregulation promotes cancer aggressiveness in pancreatic cancer.
PI3K/Akt pathway
PTEN
Pancreatic cancer
cancer malignancy
miR-380-3p
Journal
Bioengineered
ISSN: 2165-5987
Titre abrégé: Bioengineered
Pays: United States
ID NLM: 101581063
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
29
6
2022
Statut:
ppublish
Résumé
N(6)-methyladenosine (m6A)-modified microRNAs (miRNAs) are relevant to cancer progression. Also, although the involvement of miR-380-3p in regulating cancer progression in bladder cancer and neuroblastoma has been preliminarily explored, its role in other types of cancer, such as pancreatic cancer (PC), has not been studied. Thus, this study aimed to investigate the role of miR-380-3p in regulating PC progression. Here, through performing Real-Time qPCR, we evidenced that miR-380-3p was significantly upregulated in the clinical pancreatic cancer tissues and cells compared to their normal counterparts. Interestingly, miR-380-3p was enriched with m6A modifications, and elimination of m6A modifications by deleting METTL3 and METTL14 synergistically suppressed miR-380-3p expressions in PC cells. Next, the gain and loss-of-function experiments verified that knockdown of miR-380-3p suppressed cell proliferation, epithelial-mesenchymal transition (EMT), and tumorigenesis in PC cells
Identifiants
pubmed: 35758158
doi: 10.1080/21655979.2022.2088497
pmc: PMC9342193
doi:
Substances chimiques
MIRN380 microRNA, human
0
MicroRNAs
0
N-methyladenosine
CLE6G00625
Methyltransferases
EC 2.1.1.-
METTL3 protein, human
EC 2.1.1.62
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Adenosine
K72T3FS567
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
14460-14471Références
JAMA. 2021 Sep 7;326(9):851-862
pubmed: 34547082
Mol Cancer. 2020 Jul 29;19(1):118
pubmed: 32727463
Gut. 2020 Dec;69(12):2180-2192
pubmed: 32312789
Gut. 2022 Jan;71(1):129-147
pubmed: 33568427
J Exp Clin Cancer Res. 2020 Nov 5;39(1):232
pubmed: 33153498
IUBMB Life. 2020 May;72(5):884-898
pubmed: 32078236
Arterioscler Thromb Vasc Biol. 2021 Jun;41(6):e325-e337
pubmed: 33910374
BMC Genomics. 2019 Dec 10;20(1):962
pubmed: 31823726
Cell Death Differ. 2021 Oct 9;:
pubmed: 34628486
Nucleic Acids Res. 2021 Jul 21;49(13):7239-7255
pubmed: 34023900
J Exp Clin Cancer Res. 2021 Sep 8;40(1):284
pubmed: 34496932
Cancer Discov. 2021 Feb;11(2):480-499
pubmed: 33023892
Gut. 2021 Sep;70(9):1698-1712
pubmed: 33219048
J Exp Med. 2020 Sep 7;217(9):
pubmed: 32510550
RNA Biol. 2021 Dec;18(12):2226-2235
pubmed: 33980133
Cancer Treat Rev. 2020 Jun;86:102016
pubmed: 32247999
Mol Ther Nucleic Acids. 2020 Oct 22;23:27-41
pubmed: 33376625
Cancer Commun (Lond). 2021 Mar;41(3):199-217
pubmed: 33506604
Front Endocrinol (Lausanne). 2022 Mar 31;13:847760
pubmed: 35432196
Mol Cancer. 2020 Jan 6;19(1):3
pubmed: 31906946
Theranostics. 2021 Jan 1;11(3):1100-1114
pubmed: 33391523
Oncogene. 2020 Oct;39(42):6529-6543
pubmed: 32917956
J Exp Clin Cancer Res. 2020 Jan 17;39(1):16
pubmed: 31952541
Toxicol Sci. 2019 Jul 31;:
pubmed: 31368498
Cancer Sci. 2020 Oct;111(10):3435-3444
pubmed: 32750177
Nat Commun. 2021 Mar 2;12(1):1394
pubmed: 33654093
Nat Commun. 2019 May 6;10(1):2065
pubmed: 31061416
Drug Dev Res. 2022 Feb;83(1):64-74
pubmed: 34189738
Biomed Pharmacother. 2019 Apr;112:108613
pubmed: 30784918
Gastroenterology. 2021 Apr;160(5):1771-1783.e1
pubmed: 33421513
Mol Cancer. 2017 Feb 28;16(1):52
pubmed: 28245823
Nucleic Acids Res. 2019 Nov 18;47(20):e126
pubmed: 31504776
Mol Cell. 2019 Jun 20;74(6):1278-1290.e9
pubmed: 31031083
Proc Natl Acad Sci U S A. 2020 Dec 8;117(49):31189-31197
pubmed: 33229547
Mol Cancer. 2020 May 19;19(1):91
pubmed: 32429928
Biol Res. 2020 Aug 20;53(1):35
pubmed: 32819442
Bioengineered. 2022 May;13(5):11373-11387
pubmed: 35521747
Cancer Gene Ther. 2021 Apr;28(3-4):335-349
pubmed: 32939058
Cell Death Dis. 2020 Aug 18;11(8):643
pubmed: 32811810
Ann Transl Med. 2020 Mar;8(6):387
pubmed: 32355831
Mol Ther. 2022 Mar 2;30(3):1119-1134
pubmed: 34998954
Cell Cycle. 2020 Dec;19(24):3563-3580
pubmed: 33283616
Mol Cancer. 2019 Oct 13;18(1):142
pubmed: 31607270
Biochem Pharmacol. 2021 Jul;189:114357
pubmed: 33279497
Nucleic Acids Res. 2021 Jan 8;49(D1):D134-D143
pubmed: 32821938
J Hematol Oncol. 2019 Nov 22;12(1):121
pubmed: 31757221